We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
11:30
-
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
11:45
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
-
Theatre 2 (Rubi)30 mins
- Operational & Commercial Performance
12:00
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
12:15
-
Theatre 1 (Zafir)30 mins
- Cell & Gene Therapy Clinical Pathways
A view on the latest clinical trials, innovations and trends coming out of Europe, US and further afield and what practical coordination would make cross-border trials, faster, simpler and more attrac ... -
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
Cost isn’t just efficiency it’s architecture: How advanced facilities change the cost curve of CGT production, from automation and digitalisation to scale, standardisation and multi-product flexibilit ...
12:30
-
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
CAR-T has delivered transformative clinical outcomes, but its manufacturing model still resembles the early biologics era: complex, bespoke, variable and difficult to scale economically. Antibodies be ...
12:45
-
Exhibition Hall75 mins
- Networking Break
13:00
-
Panel: Designing advanced therapies that survive scale: from early decisions to commercial readinessWorkshop Room (Rossini 1&2)60 mins
- Workshop
Advanced therapy developers face intense pressure to accelerate timelines, but speed without early discipline across CMC, delivery, analytics, and manufacturing can introduce risks that surface later ...
14:00
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
• Development of human receptor–targeting capsids (TfR1 CapX) to enable efficient, translatable blood–brain barrier crossing and broad CNS gene delivery• Preclinical data showing improved CNS biodistr ... -
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
Scaling MSC manufacturing remains a major challenge in cell therapy development, particularly as processes move from early research into clinical and commercial production. This presentation reviews f ...
14:15
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
The uncomfortable truth: Where early CMC and manufacturing assumptions quietly inflated cost of goods as programmes moved toward later-stage development and why these issues only surfaced under scale ... -
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
-
Workshop Room (Rossini 1&2)10 mins
- Innovation Zone
14:25
-
Workshop Room (Rossini 1&2)20 mins
- Innovation Zone
14:30
-
Theatre 1 (Zafir)30 mins
- Cell & Gene Therapy Clinical Pathways
AAV demand has outpaced infrastructure: Why current production models struggle to meet clinical and commercial demand and which upstream, downstream and process innovations are finally closing the eff ... -
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
14:45
-
Theatre 2 (Rubi)45 mins
- Operational & Commercial Performance
Session Overview Advanced therapies are stretching not just science and regulation but the very design of capital itself. Across Europe, a growing sentiment has emerged that traditional venture capita ... -
Workshop Room (Rossini 1&2)10 mins
- Innovation Zone
14:55
-
Workshop Room (Rossini 1&2)10 mins
- Innovation Zone
Allogenetics introduces ex vivo transplant gene therapy in transplant medicine. We have shown for the first time that fine-tuning of antigen-presentation by addressing the universal MHC-system leads t ...